US 10406226
Method of manufacturing VEGF antagonist fusion proteins
granted A61KA61K31/4172A61K31/7012
Quick answer
US patent 10406226 (Method of manufacturing VEGF antagonist fusion proteins) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/4172, A61K31/7012, A61K38/16, A61K38/179